Neogen (NEOG) Stock Price, News & Analysis

2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Neogen in the last twelve months. There are currently 1 hold rating and 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" NEOG shares.
View NEOG analyst ratings or view top-rated stocks.

2 Wall Street analysts have issued 1 year price targets for Neogen's stock. Their NEOG share price targets range from $17.00 to $28.00. On average, they predict the company's stock price to reach $22.50 in the next twelve months. This suggests a possible upside of 88.6% from the stock's current price.
View analysts price targets for NEOG or view top-rated stocks among Wall Street analysts.

Neogen's stock was trading at $20.11 at the beginning of 2024. Since then, NEOG stock has decreased by 40.7% and is now trading at $11.93.
View the best growth stocks for 2024 here.

The company is scheduled to release its next quarterly earnings announcement on Thursday, July 25th 2024.
View our NEOG earnings forecast.

Neogen Co. (NASDAQ:NEOG) released its quarterly earnings results on Tuesday, April, 9th. The company reported $0.12 earnings per share for the quarter, missing analysts' consensus estimates of $0.14 by $0.02. The business had revenue of $228.80 million for the quarter, compared to analysts' expectations of $230.01 million. Neogen had a net margin of 0.17% and a trailing twelve-month return on equity of 3.35%. The company's revenue for the quarter was up 4.8% on a year-over-year basis. During the same period last year, the company earned $0.12 earnings per share.

ETFs with the largest weight of Neogen (NASDAQ:NEOG) stock in their portfolio include iShares Emergent Food and AgTech Multisector ETF (IVEG), VanEck Agribusiness ETF (MOO), Franklin U.S. Small Cap Multifactor Index ETF (FLQS), Vanguard Russell 2000 Value ETF (VTWV) and Invesco S&P MidCap 400 GARP ETF (EWMC).Pacer BioThreat Strategy ETF (VIRS).

Neogen's stock split on Tuesday, January 2nd 2018. The 4-3 split was announced on Friday, December 8th 2017. The newly issued shares were distributed to shareholders after the market closes on Friday, December 29th 2017. An investor that had 100 shares of stock prior to the split would have 133 shares after the split.

Neogen updated its FY 2024 earnings guidance on Tuesday, April, 9th. The company provided EPS guidance of for the period. The company issued revenue guidance of $910.0 million-$920.0 million, compared to the consensus revenue estimate of $938.2 million.

31 employees have rated Neogen Chief Executive Officer John Adent on Glassdoor.com. John Adent has an approval rating of 56% among the company's employees. This puts John Adent in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

Based on aggregate information from My MarketBeat watchlists, some companies that other Neogen investors own include NVIDIA (NVDA), NIKE (NKE), Pfizer (PFE), AT&T (T), AbbVie (ABBV), Boeing (BA), JPMorgan Chase & Co. (JPM), W. P. Carey (WPC), Advanced Micro Devices (AMD) and Costco Wholesale (COST).

Neogen's stock is owned by a number of institutional and retail investors. Top institutional shareholders include Bridge City Capital LLC (0.08%), Northwest Investment Counselors LLC (0.03%), Diversified Trust Co (0.02%), AlphaMark Advisors LLC (0.01%) and Moody National Bank Trust Division (0.00%). Insiders that own company stock include Darci L Vetter, David H Naemura, Douglas Edward Jones, James C Borel, James P Tobin, Jason Warren Lilly, John Edward Adent, Ronald D Green, Steven J Quinlan, Terri A Morrical and William T Boehm.
View institutional ownership trends.

Shares of NEOG stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.